Financial Performance - The company's revenue for Q1 2025 was CNY 208,475,751.58, representing a year-on-year increase of 4.28% compared to CNY 199,920,896.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 61,216,292.50, a significant increase of 36.68% from CNY 44,788,913.62 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 58,348,017.52, reflecting a 54.45% increase from CNY 37,777,315.36 year-on-year[4] - The basic earnings per share increased to CNY 0.77, up 37.50% from CNY 0.56 in the same period last year[4] - The weighted average return on net assets rose to 1.59%, an increase of 0.42 percentage points from 1.17% in the previous year[4] - Total revenue for Q1 2025 reached ¥208,475,751.58, an increase of 4.3% compared to ¥199,920,896.28 in Q1 2024[19] - Net profit for Q1 2025 was ¥61,179,020.99, up 37.0% from ¥44,644,329.67 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.77, compared to ¥0.56 in Q1 2024, representing a 37.5% increase[21] - The company reported a significant increase in investment income, rising to ¥517,478.78 from ¥4,204,435.81 in the previous year[20] - The company’s total comprehensive income for Q1 2025 was CNY 66,119,495.05, compared to CNY 51,953,066.44 in Q1 2024[30] Cash Flow and Assets - The net cash flow from operating activities decreased by 72.51%, amounting to CNY 10,745,190.17 compared to CNY 39,081,462.52 in the same period last year[4] - Operating cash inflow for Q1 2025 was CNY 218,921,277.15, an increase from CNY 203,888,757.66 in Q1 2024, representing a growth of approximately 7.5%[23] - Net cash flow from operating activities for Q1 2025 was CNY 10,745,190.17, a significant decrease from CNY 39,081,462.52 in Q1 2024, indicating a decline of about 72.5%[24] - Cash inflow from investment activities in Q1 2025 was CNY 599,607,891.80, down from CNY 866,426,537.50 in Q1 2024, reflecting a decrease of approximately 30.9%[24] - Cash and cash equivalents amounted to CNY 896.27 million, down from CNY 920.38 million, reflecting a decrease of 2.41%[13] - Cash and cash equivalents at the end of Q1 2025 were CNY 876,232,053.16, down from CNY 1,239,986,125.64 at the end of Q1 2024, a decline of approximately 29.3%[24] - The company experienced a net decrease in cash and cash equivalents of -CNY 24,104,902.43 in Q1 2025, compared to -CNY 76,639,100.24 in Q1 2024, showing an improvement in cash flow management[24] - Total assets at the end of the reporting period were CNY 4,204,870,426.23, a slight increase of 0.45% from CNY 4,186,020,158.25 at the end of the previous year[5] - Total assets amounted to ¥4,204,870,426.23, slightly up from ¥4,186,020,158.25[16] - Current assets totaled CNY 3,399,417,450.72 as of March 31, 2025, compared to CNY 3,282,646,855.51 at the end of 2024, marking an increase of approximately 3.5%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,431[8] - The company has a total of 52.76% of shares controlled by its actual controllers, indicating a strong ownership structure[11] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 18.49 million shares, representing a substantial stake[11] - The company has a repurchase account holding 1.41 million shares, accounting for 1.78% of total shares, which is not included in the top ten shareholders[12] - The company has signed a "consensus action agreement" among its major shareholders, ensuring aligned interests in management and strategic decisions[11] Expenses and Liabilities - Research and development expenses totaled CNY 21,152,185.22, accounting for 10.15% of revenue, down from 11.58% in the previous year[5] - Total operating costs decreased to ¥143,277,319.88 from ¥144,138,319.97, reflecting a slight reduction of 0.6%[19] - Research and development expenses for Q1 2025 were ¥21,152,185.22, a decrease of 8.7% from ¥23,156,697.04 in Q1 2024[20] - Total liabilities decreased to ¥257,185,156.86 from ¥302,599,855.36, indicating a reduction of 15.0%[16] - Total liabilities decreased to CNY 161,338,001.91 as of March 31, 2025, from CNY 171,803,877.54 at the end of 2024, indicating a reduction of about 6.1%[28] - The company experienced a decrease in sales expenses, which rose to ¥14,008,023.23 from ¥10,813,141.14, indicating a 29.8% increase[19] - The company experienced a significant decrease in financial expenses, reporting CNY -587,080.88 in Q1 2025 compared to CNY -4,403,744.85 in Q1 2024[29]

Dividend Distribution - The company plans to distribute a cash dividend of RMB 15 per 10 shares, totaling RMB 116,802,501, which accounts for 38.62% of the net profit attributable to shareholders for the year[6]. - The total cash dividend for the year, including the mid-year distribution, amounts to RMB 233,139,052.50, representing 89.29% of the net profit attributable to shareholders[7]. - The company plans to distribute a total cash dividend of 233.14 million RMB for the 2024 fiscal year, representing 77.08% of the net profit attributable to shareholders[43]. - The company aims to distribute at least 30% of the average annual distributable profit over the last three years in cash dividends[196]. - The proposed cash dividend for 2024 is 15 yuan per 10 shares, totaling approximately 116.8 million yuan, which represents a significant portion of the net profit attributable to shareholders[200]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 25%[19]. - The company's operating revenue for 2024 reached ¥866,582,952.58, representing a 14.83% increase compared to ¥754,696,888.86 in 2023[26]. - Net profit attributable to shareholders increased by 67.50% to ¥302,471,981.38 from ¥180,576,190.21 in the previous year[26]. - The net profit after deducting non-recurring gains and losses increased by 61.67% to ¥237,533,231.26 from ¥146,923,088.76 in 2023[26]. - Basic earnings per share rose by 67.54% to ¥3.82, up from ¥2.28 in 2023[28]. - The company's total assets at the end of 2024 were ¥4,186,020,158.25, a 1.70% increase from ¥4,116,057,772.87 in 2023[27]. - The company's net assets attributable to shareholders rose to 3.88 billion yuan, marking a 1.47% increase year-to-date[112]. - The company reported a net income of $300 million, a 10% increase compared to the same quarter last year[46]. - The company achieved a main business revenue of 862 million RMB, a year-on-year increase of 14.64%[38]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 5 million, which is a 15% increase compared to the previous quarter[19]. - User data showed an increase in active users to 10 million, up from 8 million last year, indicating a 25% growth in user base[46]. - The company is expanding its market presence in Europe, targeting a 10% market share by the end of the fiscal year[19]. - The company plans to enhance its distribution network, aiming for a 20% increase in operational efficiency by the end of the year[19]. - The company is focusing on strategic partnerships to enhance distribution channels, aiming for a 30% increase in distribution efficiency[46]. Research and Development - The company launched 107 new products during the reporting period, with R&D investment amounting to 95.82 million RMB, accounting for 11.06% of revenue[40]. - The company is investing 100 million RMB in new technology development to improve diagnostic accuracy and speed[19]. - The company aims to invest 344.65 million in research and development to drive technological advancements and product innovation[169]. - The company has developed over 300 types of self-produced biological raw materials, achieving a self-supply rate exceeding 80%[55]. - The company has developed a range of biomarkers for inflammation, cardiac, anemia, hormone, thyroid function, tumor markers, and diabetes, with most projects now in mass production[71]. Compliance and Governance - The company has established a governance structure that ensures clear division of responsibilities among shareholders, the board of directors, and management, ensuring orderly operations[162]. - The company is focused on ensuring compliance with legal and regulatory requirements during shareholder meetings[165]. - The company has implemented a comprehensive quality management system, including over 30 procedural control documents to ensure product quality and safety[98]. - The company has successfully passed multiple quality audits and inspections, meeting the requirements of various quality management systems[97]. - The company emphasizes transparency and stability in its profit distribution policy, considering various factors such as shareholder expectations and external financing conditions[198]. Strategic Initiatives - A strategic acquisition of a smaller biotech firm is anticipated to enhance the company's R&D capabilities and product offerings, with an expected completion date in Q2 2024[19]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, targeting a 10% increase in overall market capitalization[172]. - The company plans to enhance operational efficiency, targeting a reduction in operational costs by 8% through process optimization[171]. - The company aims to evolve POCT from a "diagnostic tool" to a "health management infrastructure" driven by inclusive, intelligent, and compliant trends[61]. - The company plans to introduce at least one new product each month to enrich its product line and respond to market changes[157]. Market Trends and Industry Insights - The global IVD market is projected to reach $109.2 billion by 2024, with a CAGR of approximately 2.5%, expected to reach $135.1 billion by 2029[51]. - The Chinese IVD market is estimated to be around 120 billion RMB in 2024, maintaining a growth rate of over 15% in recent years, significantly above the global average[53]. - The demand for IVD reagents is increasing due to rising health awareness and the growing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer[152]. - The IVD industry is expected to benefit from improved regulatory frameworks and faster approval processes for innovative products, enhancing market entry speed[152]. - The industry is moving towards precision, intelligence, and diversification, driven by technological innovation, market demand, and policy support[155].

2024年度 ESG暨可持续发展报告 股票简称：奥泰生物 股票代码：688606 杭州奥泰生物技术股份有限公司 HANGZHOU ALLTEST BIOTECH CO.,LTD CONTENTS 目录 | 01 关于本报告 | | 18｜研精覃思·至臻求索 | | 30｜人才培养·共创佳绩 | | --- | --- | --- | --- | --- | | 02 董事长致辞 | | 19｜创新研发 | 21｜研发能力 | 31｜人才培养 | | 03｜奥泰风华·责行天下 | | 20｜研发平台 | 22｜知识产权 | 33｜员工关怀 | | 04｜企业简介 | 11｜风险控制 | 23｜产品升级·互利共赢 | | 34｜守护健康 | | 05｜发展历程 | 12｜内控管理 | | 24｜产品介绍 | 35｜低碳发展·响应双碳目标 | | 06｜企业文化 | 13｜可持续发展管理 | | 26｜资质证书 | 36｜应对气候变化 | | 07｜社会认可 | 14｜实质性议题 | | | | | | 15｜信息安全保护与商业道德 | | 27｜质量管理 | 37｜风险管理 | | 08｜公司治理 | 16｜党建 ...

关于杭州奥泰生物技术股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同会计师事务所 (特殊普通合伙) 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn） "进行查 " 目 录 关于杭州奥泰生物技术股份有限公司 2024 年度募集资金 存放与实际使用情况鉴证报告 杭州奥泰生物技术股份有限公司 2024 年度募集资金 存放与实际使用情况的专项报告 Grant Thornton 47 日 致同会计师事务所(特殊普通合伙) 国北京 朝阳区建国门外大街 2 广场 5 层 邮编 100004 86 10 8566 558 关于杭州奥泰生物技术股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 致同专字（2025）第 332A010905 号 1-7 杭州奥泰生物技术股份有限公司全体股东: 我们接受委托,对后附的杭州奥泰生物技术股份有限公司(以下简称奥 泰生物公司）《2024年度募集资金存放与实际使用情况的专项报告》（以下 简称 ...

（一）实际募集资金金额、资金到账时间 证券代码：688606 证券简称：奥泰生物 公告编号：2025-013 杭州奥泰生物技术股份有限公司 2024年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意杭州奥泰生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]495 号）核准同意，公司首次公 开发行人民币普通股 13,500,000 股，发行价格 133.67 元/股，新股发行募集资 金总额为 1,804,545,000.00 元，扣除发行费用 161,278,093.75 元后,募集资金 净额为 1,643,266,906.25 元，上述募集资金已于 2021 年 3 月 19 日全部到位， 并由致同会计师事务所（特殊普通合伙）对公司募集资金的资金到位情况进行了 审验，出具致同验字【2021】第 332C000116 号《验资报告》。公司已按规定对 募集资金进行了专户存储，公司与保荐机构、募集资金专户开户银行签 ...

您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 您可 目 录 关于杭州奥泰生物技术股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所 (特殊普通合伙) 关于杭州奥泰生物技术股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字（2025）第 332A010906 号 杭州奥泰生物技术股份有限公司全体股东: 我们接受杭州奥泰生物技术股份有限公司（以下简称"奥泰生物公司"） 委托，根据中国注册会计师执业准则审计了奥泰生物公司 2024年 12月 31日 的合并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流 量表、合并及公司股东权益变动表和财务报表附注,并出具了致同审字(2025) 第 332A018640 号 无保留意见审计报告。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监 管要求》等有关规定,奥泰生物公司编制了本专项说明所附的杭州奥泰生物 技术股份有限公司 2024年度非经营性资金占用及其他关联资金往来情况汇总 表（以下简称"汇总表"）。 编制和对外披露汇总表,并确 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-017 杭州奥泰生物技术股份有限公司 关于召开 2024 年度暨 2025 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 05 月 09 日(星期五) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 04 月 29 日(星期二)至 05 月 08 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 yanping.fu@ alltests.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 杭州奥泰生物技术股份有限公司（以下简称"公司"）已于 2025 年 04 月 29 日发布公司 2024 年年度报告以及 2025 年第一季度报告，为便于广大投资者更全 面深入地了解公司 ...

经公司独立董事周亚力先生和郑展望先生自查及董事会核查独立董事及其 直系亲属和主要社会关系人员的任职经历以及独立董事签署的相关自查文件，董 事会认为公司全体独立董事不存在《上市公司独立董事管理办法》规定的不得担 任独立董事的情形，在担任公司独立董事期间，独立董事已严格遵守中国证监会 和上海证券交易所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责， 作出独立判断时不受公司主要股东、实际控制人或其他与公司存在利害关系的单 位或个人的影响。 综上，公司董事会认为，公司全体独立董事符合《上市公司独立董事管理办 法》等法律法规及《杭州奥泰生物技术股份有限公司章程》中关于独立董事的任 职资格及独立性的要求。 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》的规定，独立董事应当每年对独立性情况进行自 查，并将自查情况提交董事会。董事会应当每年对在任独立董事独立性情况进行 评估并出具专项意见。基于此，杭州奥泰生物技术股份有限公司（以下简称"公 司"）董事会根据法规并结合独立董事出具的《独立董事独立性自查情况表》，就 公司独立董事周亚力先 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-012 杭州奥泰生物技术股份有限公司 关于续聘 2025 年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟聘任的 2025 年度审计机构（会计师事务所）名称：致同会计师事务 所（特殊普通合伙） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 会计师事务所名称：致同会计师事务所（特殊普通合伙）（以下简称"致 同"） 成立日期：1981 年(工商登记日期：2011 年 12 月 22 日) （二）项目信息 注册地址：北京市朝阳区建国门外大街 22 号赛特广场五层 首席合伙人：李惠琦 执业证书颁发单位及序号：北京市财政局 NO 0014469 截至 2024 年末，致同从业人员近六千人，其中合伙人 239 名，注册会计师 1,359 名，签署过证券服务业务审计报告的注册会计师超过 400 人。致同 2023 年度业务收入 27.03 亿元，其中审计业务收入 22.05 亿元，证券业务收入 5.02 亿元。2023 年 ...

公司代码：688606 公司简称：奥泰生物 杭州奥泰生物技术股份有限公司 2024年度内部控制评价报告 杭州奥泰生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...